« Zurück
Startseite /
Anti-SARS-CoV Spike (16aa - Intermediate Domain) - 0.1 mg

Anti-SARS-CoV Spike (16aa - Intermediate Domain) - 0.1 mg

ArtNr	LEIN-S541-0.1mg
Hersteller	Leinco Technologies
Menge	0.1 mg
Quantity options	0.1 mg 20 ug
Kategorie	Antibodies Western Blot ELISA Primary Antibodies Immunostaining
Typ	Antibody Primary
Applikationen	WB, ELISA
Specific against	Virus
Host	Rabbit
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Applications	Quality Tested by Leinco ELISA WB
Manufacturer - Category	Primary Monoclonal Antibodies>Infectious Diseases\|SARS-CoV-2
Manufacturer - Targets	SARS Spike
Country of Origin	USA
Shipping Temperature	Next Day Ambient
Storage Conditions	This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Product Description	A novel coronavirus has recently been identified as the causative agent of SARS-CoV. Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS can be mediated by the binding of the viral spike protein, a glycosylated protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.
Background	A novel coronavirus has recently been identified as the causative agent of SARS-CoV. Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS can be mediated by the binding of the viral spike protein, a glycosylated protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.
PubMed	SARS Spike
Manufacturer - Research Area	COVID-19, Infectious Disease, Seasonal and Respiratory Infections, Viral, IVD Raw Material
Manufacturer - Specificity	Rabbit Anti-Human Severe Acute Respiratory Syndrome Spike (SARS-CoV Spike) recognizes Human SARS Spike. This polyclonal antibody was purified using affinity chromatography.
RRID	AB_2831779
Concentration	0.5 mg/ml
Formulation	This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen	Anti-SARS-CoV Spike antibody was raised against a peptide corresponding to 16 amino acids near the center of SARS-CoV Spike glycoprotein. The immunogen is located within amino acids 410-460 of SARS-CoV Spike.
Additional Information	Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Keywords	Polyclonal Antibody, SARS Spike, Human, Anti-Severe Acute Respiratory Syndrome Spike (Intermediate Domain 1) (SARS Spike), COVID-19, SARS-CoV

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

LEIN-S541-0.1mg-safety-datasheet.pdf